Cardioxyl Pharmaceuticals Secures Additional $15M in Funding

Cardioxyl Pharmaceuticals, Inc., a Chapel Hill, NC-based clinical-stage pharmaceutical company developing novel therapeutic agents for the treatment of cardiovascular disease, has raised $15 million in funding.
Investors include existing backers Aurora Funds and New Enterprise Associates (NEA).
With this additional funding, Cardioxyl will execute on a Phase IIa trial for its lead drug candidate, CXL-1020, for the treatment of patients with acute decompensated heart failure (ADHF), and to continue development of its promising research portfolio.
The company has achieved positive safety and tolerability results in the first clinical study of CXL-1020.

Join the discussion